3 Marijuana Stocks To Watch As Featured On The Motley Fool

We Are Not Just a Medical Marijuana StockSubsys, used for breakthrough cancer pain in opioid-tolerant patients, is by far the company’s biggest-selling product, accounting for over 99% of total revenue. Insys also sells generic Dronabinol SG, a second-line cannabinoid drug used for chemotherapy-induced nausea and vomiting and anorexia associated with weight loss in patients with AIDS.

Dronabinol SG isn’t making a big financial impact for Insys, but the company does have two other marijuana-based drugs in development that could one day be winners. First, Insys is in phase 2/3 clinical studies for Dronabinol Oral Solution, an orally administered liquid form of the drug that looks to be more effective than the capsule version.

Second, like GW Pharmaceuticals, Insys won FDA Orphan Drug Designation for its cannabidiol oral solution as a potential treatment for Dravet syndrome and Lennox-Gastaut syndrome.

3.Cara Therapeutics

Cara Therapeutics doesn’t have any products on the market yet, so the company’s financial position isn’t as solid as the other two on our list.

To read more, visit http://www.fool.com/investing/general/2015/07/10/3-marijuana-stocks-to-watch.aspx

Posted in: News

Comments are closed.